NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 4231/2055E

Ü.C		CERT	TIFICATE OF MA	ILING UNDER 37 C	FR 1.10			
U.S. P	I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United							
States P	ostal Se	rvice using Express Mail	to Addressee Service	e, under 37 C.F.R. Sec	tion 1.10, Express Mail Label No.			
EV242756476US on this date, March 30, 2004, postage prepaid, in an envelope addressed to Mail Stop Patent Application,								
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Amy Decloux								
				ame of Person Mailing Paper		<u>F</u> 0		
				Orny Dellor	<u> </u>	- s <u>L</u>		
Mail St	on Pate	nt Application	51	gnature of Person Mailing P	aper	->.⊘		
	-	for Patents)/8		
	P.O. Box 1450							
Alexan		A 22313-1450		c				
	Enclos	sed herewith is a new p						
		First Named Inventor						
		Title of Invention: A Method for the Detection of Type II Diabetes Related Gene Transcripts in Blood						
Type:		New Continue of						
		Continuation of: Continuation-in-Part of:						
	\boxtimes	Divisional of: Serial No. Not Yet Assigned; Atty. Docket No. 4231/2055B, Filed March 12, 2004, Entitled: A						
					Related Gene Transcripts in Blood			
	which is hereby incorporated by reference in is entirety into the application filed herewith;							
		d includes the following papers:						
1.	\boxtimes	Specification 272 pages (including specification, claims, abstract)/53 claims (21 independent)						
2.	\boxtimes	Declaration/Power of Attorney is: Executed Unexecuted Executed copy from Parent Application NOT included, but deferred under 37 C.F.R. § 1.53(f).						
3.	\boxtimes	34 Distinct sheets of Formal Informal Drawings						
4.	\boxtimes	Application Data Sheet						
5		Preliminary Amendment.						
6.		Information Disclosure Statement Form 1449 A copy of each cited prior art reference (as necessary)						
7.	П	Assignment with Recordation Cover Sheet.						
8.	\boxtimes	Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):						
				3				
		Country	Applicati	on Number	Date of Filing (day, month, year	ar)		
	US		60/271,955		28 February, 2001			
	US		60/305,340		13 July, 2001			
US		60/275,017		12 March, 2001				
	US		60/115,125 6 January, 1999					
9.	Priority is hereby claimed under 35 U.S.C. § 120 based upon the following application(s):							
	Application Number Date of Filing (day, month, year)							
10/601,518				20 June, 2003				

NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 4231/2055E

10/268,730		9 October, 2002					
10/085,783			28 February, 2002				
09/477,148				4 Janua	ry, 2000		
10.	\boxtimes	Priority is hereby claimed under 35 U.S.C. §	121 based upo	n the following	g application	(s):	
	Application Number Date of Filing (day, month, year)					ear)	
Not Yet Assigned (Atty. Docket No. 4231/2055B)			March 12, 2004				
The above applications from which priority is claimed are hereby incorporated in their entirety into the application filed herewith.							
11.	1. Priority document(s).						
12.		Microfiche Computer Program (Appendix).	ne Computer Program (Appendix).				
13.	Nucleotide and/or Amino Acid Sequence Submission. Computer Readable Copy. Paper Copy (identical to computer copy). Statement verifying identity of above copies.						
14.	Request for Non-Publication and Certification under 35 USC 122 (b)(2)(B)(i)						
15.	Statement of Small Entity Status, Pursuant to 37 C.F.R. §1.27.						
16.	16. Calculation of Fees:						
		FEES FOR	TOTAL CLAIMS	EXCESS CLAIMS	FEE	AMOUNT DUE	
Basic F	iling Fe	e (37 C.F.R. § 1.16(a))				\$770.00	
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))		260	240	\$18.00	\$4,320.00		
Indepe	ndent Cl	aims in Excess of 3 (37 C.F.R. § 1.16(b))	21	18	\$86.00	\$1,806.00	
Multiple Dependent Claims (37 C.F.R. § 1.16(d))			YE	S	\$290.00	290.00	
Subtotal - Filing Fee Due			<u>-</u>		\$7,186.00		
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)			MULTIPLY BY 0.50 \$3,593.0			\$3,593.00	
TOTAL FILING FEE DUE						\$3,593.00	
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))			0		\$40.00		
GRAND TOTAL DUE \$3,593.00							
17. PAYMENT is: ☐ The Commissioner is hereby authorized to charge any fees to Deposit Account 16-0085, Ref. 4231/2055E. ☐ not included, but deferred under 37 C.F.R. § 1.53(f).							
			` '				

NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 4231/2055E

18.	All correspondence for the attached application should be directed to: Kathleen Williams Customer Number 29933 111 Huntington Avenue Boston, MA 02199-7613			
19.	Other:			
Date:	Respectfully submitted, By: Name: Kathleen Williams			
	Registration No.: 34,380			

Atty. Docket No.:

4231/2055E

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Choong-Chin Liew

Serial No.:

Not Yet Assigned

Filed:

March 30, 2004

Entitled:

A Method for the Detection of Type II

Diabetes Related Gene Transcripts in Blood

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, Express Mail Label No. EV242756476US on this date, March 30, 2004, postage prepaid, in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Amy Decloux

Name of Person Mailing Paper

any De Clory

Signature of Person Mailing Paper

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- 1. New Patent Application Transmittal;
- 2. Patent Application, (272 pages);
- 3. Thirty-Four (34) sheets of informal drawings of Figs 1 34;
- 4. Application Data Sheet;
- 5. Non-Pub Request (Request for Certification Under 35 U.S.C. 122(b)(2)(B)(i));
- 6. Two (2) CD-ROMs (called Tables Copy 1, Tables Copy 2) in the following format:

Machine Format: IBM-PC

Operating System: MS-Windows Files Contained: See Chart Below

Size: 6.27MB

Date of Creation: March 29, 2004

and containing Tables 2 - 4. The content of each CD-ROM is identical and is as shown on the following chart:

Attorney Docket No.: 4231/2055E Filed: March 30, 2004

	TABLE	DESCRIPTION	SIZE	CREATED	Text File Name
1	2	multi-gene comparison	371,563	3/25/2004	TABLE2.TXT
2	3A	GLF 8 - hypertension	138,940	3/28/2004	TABLE3A.TXT
3	3AA	GLF 29 - asthma	36,121	3/27/2004	TABLE3AA.TXT
4	3AB	multi OA	29,898	3/27/2004	TABLE3AB.TXT
5	3AC	GL MDS vs. schizo	114,078	3/27/2004	TABLE3AC.TXT
6	3AD	steroid differential	64,646	3/27/2004	TABLE3AD.TXT
7	3B	GLF 9 - obesity	147,421	3/25/2004	TABLE3B.TXT
8	3C	GLF 10 - allergies	95,700	3/25/2004	TABLE3C.TXT
9	3D	GLF 11 - steroids	93,808	3/25/2004	TABLE3D.TXT
10	3E	GLF 12 - hypertension	314,854	3/25/2004	TABLE3E.TXT
11	3F	GLF 13 - obesity	181,310	3/25/2004	TABLE3F.TXT
12	3G	GLF 14 - diabetes	146,212	3/26/2004	TABLE3G.TXT
13	3H	GLF 15 - hyperlipidemia	165,909	3/26/2004	TABLE3H.TXT
14	31	GLF 16 - lung	92,936	3/25/2004	TABLE31.TXT
15	3J	GLF 17 - bladder	1,143,423	3/26/2004	TABLE3J.TXT
16	3K	GLF 18 - bladder	953,119	3/26/2004	TABLE3K.TXT
17	3L	GLF 19 - Coronary Art Dis.	246,178	3/26/2004	TABLE3L.TXT
18	3M	GLF 20 - rheumarth	329,672	3/26/2004	TABLE3M.TXT
19	3N	GLF 21 - depression	153,108	3/26/2004	TABLE3N.TXT
20	30	GLF 22 - rheumarth	49,043	3/26/2004	TABLE3O.TXT
21	3P	GLF hypertension 577 only	84,945	3/26/2004	TABLE3P.TXT
22	3Q	GLF OA hypertension shared	33,081	3/26/2004	TABLE3Q.TXT
23	3R	GL obesity 519	79,544	3/26/2004	TABLE3R.TXT
24	3S	GL obesity shared 152	24,583	3/26/2004	TABLE3S.TXT
25	3T	GL allergy specific	39,547	3/25/2004	TABLE3T.TXT
26	3U	GL allergy OA shared 241	35,603	3/25/2004	TABLE3U.TXT
27	3V	GL steroid 362	54,954	3/26/2004	TABLE3V.TXT
28	3W	GL OA steroid shared	31,459	3/27/2004	TABLE3W.TXT
29	3X	GLF 26 - liver cancer	435,093	3/27/2004	TABLE3X.TXT
30	3Y	GLF 27 - schizophrenia	578,949	3/26/2004	TABLE3Y.TXT
31	3Z	GLF 28 - chagas	202,477	3/28/2004	TABLE3Z.TXT
32	4	sequence listing	114,765	3/11/2004	TABLE4.TXT

Attorney Docket No.: 4231/2055E

Filed: March 30, 2004

7. Return Post Card.

Pursuant to 37 C.F.R. § 1.27, Applicant claims small entity status.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 4231/2055E. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: 3-30-04

Name: Kathleen Williams Registration No.: 34,380 Customer No.: 29933 Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

Express Mail Label Number: EV242756476US

Date of Deposit: March 30, 2004

REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)

First Named Inventor Liew

Title: A Method for the Detection of Type II Diabetes Related Gene Transcripts in Blood

Attorney Docket Number: 4231/2055E

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b)

3-30.04

Date

Signature

Kathleen Williams

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant must notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).